Top Stories Tuesday, June 28, 2016 Roche’s new multiple sclerosis drug, which targets a form of the disease that currently has no treatments, has been given a hurry-up status from the FDA as it looks to start earning on its blockbuster potential. Tuesday, June 28, 2016 Intensity Therapeutics plans to get into the clinic with a reformulation approach to cancer immunotherapy with a new $10 million Series A financing. The round includes Dr. Declan Doogan, the former SVP and head of worldwide drug development at Pfizer, who will also join the Westport, CT, startup's board as part of the investment. Tuesday, June 28, 2016 In a move that will surprise no one after this month’s poor study, AbbVie has handed back the rights to Infinity’s lead blood cancer candidate duvelisib, while also cutting all ties with the biotech. Monday, June 27, 2016 Regulus Therapeutics shed 55% in after-hours trading on news that the FDA has placed a clinical trial hold on its lead candidate, RG-101 to treat hepatitis C. Tuesday, June 28, 2016 Despite the problems in China, Pfizer is betting big on its first biotech space in the region, stumping up £$350 million for a new biotech center that it hopes will help tap into the $185 billion China healthcare market and the promise of greater market penetration in Asia. Tuesday, June 28, 2016 The venture capital wings of Merck KGaA and Pfizer have contributed to a £12 million Series A investment in Storm Therapeutics, a spinout from the University of Cambridge that is developing small molecule modulators of RNA-modifying enzymes. Read more from EuroBiotech Report Tuesday, June 28, 2016 Some specialty pharma companies have recently put the brakes on dealmaking--but Horizon Pharma, on the other hand, may be gearing up for more. Read more from FiercePharma
| | | After a failed schizophrenia trial, Waltham, MA-based Forum Pharma is said to shut down its ops this week. Story Tel Aviv’s BioLineRx has filed for a Phase IIa trial of its experimental cancer drug BL-8040 in combination with Merck’s PD-1 drug Keytruda for patients with pancreatic cancer. Release Israel-U.S. Binational Industrial R&D (BIRD) Foundation will invest $7.5 million in 9 new projects. Statement MolecularMD has signed a collab deal with Illumina for drug-diagnostic co-development with biopharma drug programs. Release Icagen will acquire Sanofi's ultra-high-throughput biology, screening and chemistry capabilities and research facility in Arizona and collaborate in a multi-year services contract for long-term discovery services. Statement | |
|
Resources Sponsored by: SDC Interested in intended use validation of SaaS-based EDC systems? Prefer to discuss rescue study strategies and considerations? How about understanding statistical power for non-statisticians? Vote for your favorite webinar topic to be presented by SDC at DIA on June 28, 2016, 12pm EDT. Cast Your Vote Here to receive your exclusive event invitation and a recording of the webinar after the event. Sponsored by: Covance Al Blunt, MD, Executive Medical Director, Oncology at Covance discusses how the lessons learned from the past decade of developing targeted therapies are relevant to the future development of cancer immunotherapy. Download today! Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance.
BIOSPAIN 2016 September 28-30, 2016 | Bilbao, Basque Country, Spain BioImmersion: In Depth Biotech for the Non-Scientist October 5-7, 2016 | Chicago, IL 12th Public Relations & Communications Summit July 26-27, 2016 | NYC Immunotherapy: Mapping the future July 28, 2016 | Foster City, CA Master of Science in Bioinformatics at Northeastern University Fall 2016, Spring 2017 Courses Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA FierceBiotech Drug Development Forum September 19-21, 2016 | Boston, MA |
